Movano (NASDAQ:MOVE) versus Nexeon Medsystems (OTCMKTS:NXNN) Critical Comparison

Movano (NASDAQ:MOVE) and Nexeon Medsystems (OTCMKTS:NXNN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Movano and Nexeon Medsystems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Movano	N/A	-452.96%	-233.43%
Nexeon Medsystems	N/A	N/A	N/A

Institutional & Insider Ownership

16.6% of Movano shares are owned by institutional investors. 13.4% of Movano shares are owned by insiders. Comparatively, 61.2% of Nexeon Medsystems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Movano and Nexeon Medsystems, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Movano	0	0	1	0	3.00
Nexeon Medsystems	0	0	0	0	0.00

Movano presently has a consensus target price of $30.00, suggesting a potential upside of 834.58%. Given Movano’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Movano is more favorable than Nexeon Medsystems.

Risk and Volatility

Movano has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Comparatively, Nexeon Medsystems has a beta of 6.98, suggesting that its stock price is 598% more volatile than the S&P 500.

Earnings & Valuation

This table compares Movano and Nexeon Medsystems”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Movano	N/A	N/A	-$29.28 million	($6.75)	-0.48
Nexeon Medsystems	N/A	N/A	N/A	N/A	N/A

About Movano

Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medical and consumer devices. The company is involved in the development of Evie Ring, which is a wearable designed specifically for women that combines health and wellness metrics comprises resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, and menstrual symptom tracking, as well as activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking. It develops System-on-a-Chip (SoC) for blood pressure or continuous glucose monitoring (CGM) systems. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.

About Nexeon Medsystems

Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.